All relevant data are within the paper and its Supporting Information files. The data underlying the results presented in the study are included as an additional supporting file.

Introduction {#sec005}
============

Norovirus is responsible for 20 million illnesses annually in the United States, including approximately 2 million outpatient visits, and is a leading cause of acute gastroenteritis (AGE) across all age groups \[[@pone.0227890.ref001]\]. The burden of disease is substantial; children \<5 years of age have the highest rates of norovirus-associated medical visits\[[@pone.0227890.ref002]\], while older adults are at greatest risk for norovirus-associated deaths\[[@pone.0227890.ref003], [@pone.0227890.ref004]\]. Several candidate vaccines are currently in clinical trials, including an oral tablet vaccine that recently reported phase I results from a bivalent GI.1/GII.4 formulation in adults, as well as a bivalent GI.1/GII.4 consensus sequence virus-like particle intramuscular vaccine candidate that has conducted phase II trials in children, adults, and the elderly \[[@pone.0227890.ref005]--[@pone.0227890.ref007]\].

Despite the large burden of disease, practicing physicians may not be aware of the importance of norovirus as a cause of AGE. This is likely due to several factors, including the perception of the disease as mild and self-limiting, as well as the recent shift in the relative importance of norovirus following the successful implementation of the rotavirus vaccine program over the past decade, with norovirus emerging as the leading cause of medically-attended AGE in U.S. children.\[[@pone.0227890.ref003]\] Additionally, the ability of physicians to diagnose norovirus has historically been hampered by the unavailability of rapid, sensitive assays in clinical settings\[[@pone.0227890.ref008]\]. In the absence of rapid point of care assays, testing may not always be warranted, such as with patients presenting with mild to moderate illness requiring only supportive care. The interpretation of sensitive PCR-based assays can also be challenging, as multi-pathogen panels may detect organisms that are not necessarily causing disease at the time of testing. However, lack of clinical diagnostic testing greatly impacts public health surveillance efforts, which often rely on physician-ordered testing, thereby limiting development of robust disease burden estimates without implementation of resource-intensive procedures\[[@pone.0227890.ref009]\].

With the recent expansion of polymerase chain reaction (PCR)-based multi-pathogen diagnostic assays in clinical settings, the ability to detect norovirus has increased rapidly in clinical and research settings\[[@pone.0227890.ref010]\]. In this study, we aimed to understand physician use of stool diagnostic testing platforms and assess physician knowledge of norovirus and perceptions of future vaccines. Our goal was not to change physician testing practices, but rather to understand the pre-vaccine licensure knowledge and testing practices of physicians who manage AGE in the outpatient setting at a time when diagnostic testing options are expanding. Ultimately, this information will help guide educational campaigns for physicians and patients in preparation for the introduction of future norovirus vaccines. In addition, the results from this survey will inform methods for ongoing surveillance for norovirus and AGE, which can help epidemiologists to more accurately estimate the burden of disease and the impact of future vaccines.

Methods {#sec006}
=======

Study population {#sec007}
----------------

We utilized national networks of primary care pediatricians (Peds), family practice (FP), and general internal medicine (GIM) physicians who identified as members of national physician organizations (American Academy of Pediatrics \[AAP\], American Academy of Family Physicians \[AAFP\], and American College of Physicians \[ACP\], respectively). Networks were recruited previously and agreed to respond to several surveys each year. We previously demonstrated that recruited physicians were similar to their national membership with respect to provider region, practice location, and setting\[[@pone.0227890.ref011]\].

Survey development & administration {#sec008}
-----------------------------------

We developed a survey to determine physician use of diagnostic testing platforms for norovirus and other AGE pathogens, patient indications for pursuing such testing, knowledge of norovirus, and perceptions of future norovirus vaccine use. At the beginning of the survey, we defined AGE as the presence of vomiting or diarrhea lasting less than two weeks. Physicians were asked to estimate the monthly number of patients seen for any reason, for AGE, and for whom stool tests were ordered, stratified by peak norovirus season (November-April) versus non-peak season (May-October).

We used Likert scales to record physicians' perception of factors associated with likelihood of stool diagnostic testing in patients with AGE, norovirus severity of illness, agreement on need for diagnostic testing for norovirus, and perceptions of barriers to using future norovirus vaccines. Knowledge of norovirus was assessed through a series of true or false questions.

The survey was pre-tested in a national advisory committee with representation from AAP, AAFP and ACP. Following pre-testing, the survey was piloted among 25 Peds, 5 FP and 18 GIM providers. The final survey was administered from January through March 2018 by internet or mail, based on physician preference, with up to eight email or two mailed reminders. The mail protocol followed Dillman's tailored design method\[[@pone.0227890.ref012]\]. The Institutional Review Board at the University of Colorado Denver deemed this study exempt research not requiring written informed consent.

Statistical analysis {#sec009}
--------------------

Internet and mail surveys were pooled as prior research indicated the responses attained by either method are similar\[[@pone.0227890.ref012]--[@pone.0227890.ref014]\]. The monthly number of patients presenting with AGE reported by each respondent was divided by the total monthly number of patients seen to estimate a monthly percentage of patients seen with AGE. The monthly number of patients with stool tests ordered was similarly divided by the monthly number of patients seen with AGE to estimate the percentage of patients with AGE for whom a stool test was ordered. For stool diagnostic tests analysis, responses were grouped under ordered (Always, Often, and Sometimes) or not ordered (Rarely and Never). Item non-response was \<5% unless otherwise noted, and missing data were excluded from analyses. Groups were compared using Wilcoxon, chi-square and Fisher's exact tests. Ranges are reported unless there were significant differences in responses by specialty.

Results {#sec010}
=======

Overall response rate was 59% (820/1,383) ([Table 1](#pone.0227890.t001){ref-type="table"}). Peds had the highest response rate (68%, 319/466), followed by FP (58%, 266/461) and GIM (52%, 235/456).

10.1371/journal.pone.0227890.t001

###### Comparison of respondents and Non-respondents, by specialty (n = 1,383).

![](pone.0227890.t001){#pone.0227890.t001g}

                                                        Pediatrics           Family Medicine      General Internal Medicine                                                                                                                                                                                                                             
  ----------------------------------------------------- -------------------- -------------------- ------------------------------------------- --------------------------------------------- ------------------- ----------------------------------------------- ------------------- ------------------- ----------------------------------------------- --
  Gender, %                                                                                       0.73                                                                                                          0.14                                                                                    0.33                                            
                                                        Female               35                   37                                                                                        43                  36                                                                  45                  40                                              
                                                        Male                 65                   63                                                                                        57                  64                                                                  55                  60                                              
  Setting, %                                                                                      0.65                                                                                                          0.14                                                                                    **0.03**                                        
                                                        Private practice     79                   80                                                                                        69                  77                                                                  65                  75                                              
                                                        Hospital or clinic   18                   15                                                                                        23                  18                                                                  27                  17                                              
                                                        HMO                  3                    5                                                                                         8                   5                                                                   8                   8                                               
  Location, %                                                                                                                                                                                                                                                                                           0.99[\*\*](#t001fn002){ref-type="table-fn"}     
                                                        Urban                52                   56                                          0.43[\*\*](#t001fn002){ref-type="table-fn"}   34                  38                                              0.54                55                  55                                              
                                                        Suburban             46                   44                                                                                        58                  55                                                                  43                  44                                              
                                                        Rural                1                    0                                                                                         8                   7                                                                   1                   1                                               
  Region, %                                                                                       0.36                                                                                                                                                                                                  0.62                                            
                                                        Midwest              23                   18                                                                                        31                  27                                              **0.02**            24                  19                                              
                                                        Northeast            22                   18                                                                                        18                  13                                                                  23                  23                                              
                                                        South                35                   41                                                                                        27                  41                                                                  31                  35                                              
                                                        West                 29                   23                                                                                        24                  19                                                                  21                  23                                              
  Age, years, mean (sd)/ median                         50.2 (10.5) / 50.0   52.2 (10.9) / 51.0   0.06                                        55.2 (8.2) / 55.0                             56.0 (7.5) / 57.0   0.30                                            55.1 (9.1) / 57.0   56.1 (8.8) / 57.0   0.25                                            
  Number of providers in practice, mean (sd) / median   11.7 (27.8) / 6.0    11.4 (41.7) / 5.0    0.15[\*](#t001fn001){ref-type="table-fn"}   11.5 (34.6) / 6.0                             8.3 (11.5) / 4.0    **0.03[\*](#t001fn001){ref-type="table-fn"}**   19.4 (44.3) / 7.0   53.4 (491) / 5.0    **0.01[\*](#t001fn001){ref-type="table-fn"}**   

\*Wilcoxon test

\*\*Fisher's Exact test

Healthcare visits and stool tests ordered for AGE {#sec011}
-------------------------------------------------

Pediatric providers reported seeing a greater proportion of their patients for AGE than adult providers, in both peak and non-peak seasons (Peak season: Peds 9%, FP 5%, GIM 3%, p\<0.01; non-peak season: Peds 5%, FP 3%, GIM 2%, p\<0.01) ([Table 2](#pone.0227890.t002){ref-type="table"}). Overall, physicians reported infrequently ordering stool diagnostics for their patients with AGE (peak 15%, non-peak 20%; overall 17%). By specialty, GIM and FP providers were more likely to order stool tests than Peds in both peak and non-peak seasons (peak: GIM 33%, FP 22%, Peds 10%, p\<0.01, non-peak: GIM 33%, FP 29%, Peds 12%, p\<0.01), but the median number of patients with stool tests ordered overall was low (2 per month for all 3 specialties in peak season) ([Table 3](#pone.0227890.t003){ref-type="table"}). Notably, 13%-15% of Peds and FP and 53% of GIM were unable to estimate numbers of AGE patients seen and tests ordered and were excluded from the above analyses.

10.1371/journal.pone.0227890.t002

###### Monthly healthcare visits for AGE, by specialty and season.

![](pone.0227890.t002){#pone.0227890.t002g}

                    Pediatrics   Family Practice   General Internal Medicine                                        
  ----------------- ------------ ----------------- --------------------------- --------- --- ---- -------- --- ---- ----------
  Peak season       21/ 320      9                 13                          11/ 272   5   14   8/ 260   3   53   \< .0001
  Non-peak season   13/ 300      5                 13                          7/ 278    3   15   4/ 255   2   52   \< .0001

n = median number of AGE healthcare visits each month; N = median number of all healthcare visits each month.

\*% represents the median proportion of all healthcare visits that were specifically for AGE.

\*\*% missing is for each question, specialty and season.

\*\*\* Wilcoxon test

10.1371/journal.pone.0227890.t003

###### Monthly stool tests ordered among patients with AGE, by specialty and season.

![](pone.0227890.t003){#pone.0227890.t003g}

                    Pediatrics   Family Practice   General Internal Medicine                                    
  ----------------- ------------ ----------------- --------------------------- ------ ---- ---- ----- ---- ---- ----------
  Peak season       2/ 21        10                12                          2/11   22   13   2/8   33   52   \< .0001
  Non-peak season   2/ 13        12                13                          2/7    29   20   2/4   33   54   \< .0001

n = median number of stool tests ordered each month among patients with AGE; N = median number of all AGE healthcare visits each month.

\*% represents the median proportion of stool tests ordered among patients with AGE.

\*\*% missing is for each question, specialty and season

\*\*\* Wilcoxon test

Availability and ordering of specific stool diagnostic tests {#sec012}
------------------------------------------------------------

For all three specialties, stool tests were more often known to be available for ova and parasites (O&P), *Clostridioides difficile* (*C*. *difficile)*, and bacterial culture (\>95% for all specialties) in contrast to norovirus-specific tests that included multiplex PCR, norovirus antigen, and norovirus PCR only (6--33% for all specialties) ([Fig 1](#pone.0227890.g001){ref-type="fig"}). Providers in all 3 specialties reported the most uncertainty about availability of the norovirus-specific tests (checked 'not sure' if available for 45--69% of tests) compared with other, non-norovirus tests (checked 'not sure' if available for \<3% of tests). Among physicians reporting a given test was available, few physicians of any specialty reported ordering norovirus PCR (5%-23%) or norovirus antigen (13%-37%) tests ([Fig 2](#pone.0227890.g002){ref-type="fig"}).

![Availability of stool diagnostic tests in outpatient clinical practice, by specialty.\
Available refers to the proportion of providers who said they had each stool diagnostic test available for testing when managing patients with AGE in the outpatient setting. Possible responses were Available, Not available, and Not sure. GIM = General Internal Medicine; FP = Family Practice; Peds = Pediatricians.](pone.0227890.g001){#pone.0227890.g001}

![Stool tests ordered by specialty among providers for whom test is reported to be available.\
"Ordered" refers to the proportion of providers who reported a specific stool diagnostic test was available and that they ordered the test always, often or sometimes when managing patients with AGE in the outpatient setting. GIM = General Internal Medicine; FP = Family Practice; Peds = Pediatricians.](pone.0227890.g002){#pone.0227890.g002}

Factors associated with physician ordering stool diagnostic testing {#sec013}
-------------------------------------------------------------------

Factors most often reported as greatly increasing the likelihood of testing with minimal differences between specialties included patient history of travel to a high risk area (71--76%), immunocompromised patient (61--69%), and clinical suspicion of a pathogen that can be treated with antibiotics or antiparasitics (56--65%) ([Fig 3](#pone.0227890.g003){ref-type="fig"} and [S1 Fig](#pone.0227890.s002){ref-type="supplementary-material"}). Peds more often reported likelihood of testing if there was blood in stool than other specialties (Peds 74%, FP 59%, GIM 49%, p\<0.01). In contrast to Peds, FP and GIM more often reported greatly increased likelihood of testing if there was a history of recent antibiotic use (Peds 33%, FP 66%, GIM 74%, p\<0.01), history of recent hospitalization (Peds 30%, FP 61%, GIM 67%, p\<0.01), consideration of inpatient admission (Peds 38%, FP 57%, GIM 56%, p\<0.01), or fever ≥38.5 C (Peds 13%, FP 29%, GIM 38%, p\<0.01). For all three specialties, factors most often reported as greatly decreasing the likelihood of testing included presence of vomiting without diarrhea (44--49%) and presence of vomiting and diarrhea together (7--11%).

![Factors associated with likelihood of stool diagnostic testing for AGE, by specialty.\
Other factors that were asked about that did not greatly increase stool diagnostic ordering included patient age, signs of moderate to severe dehydration, presence of mucous in stools, severe abdominal cramping, abdominal tenderness on exam, and when an outbreak of AGE is occurring. Data available in [S1 Fig](#pone.0227890.s002){ref-type="supplementary-material"}.](pone.0227890.g003){#pone.0227890.g003}

Perceptions of norovirus diagnostic testing {#sec014}
-------------------------------------------

Most providers agreed (strongly or somewhat) that norovirus testing "is helpful, because if it is positive, it helps rule out bacterial or other pathogens as causes" (57--59%). However, the majority of providers agreed norovirus testing is "usually not indicated because the results won't change my management of the patient" (79--90%) and "is usually not indicated because it is a self-limited illness" (77--86%).

Physician knowledge of norovirus {#sec015}
--------------------------------

Most providers answered questions on norovirus treatment, immunity, transmission, and environmental persistence correctly (76--96%) ([Table 4](#pone.0227890.t004){ref-type="table"}). Although two-thirds of providers knew that "After the diarrhea and vomiting from norovirus infection resolve, patients are no longer contagious" was incorrect, approximately one-third of providers answered incorrectly or did not know the answer (30--38%). Most providers were unaware that norovirus is the leading cause of AGE across all age groups (80--89%) and that alcohol-based hand sanitizers are ineffective against norovirus (51--66%).

10.1371/journal.pone.0227890.t004

###### Physician knowledge of norovirus, by specialty.

![](pone.0227890.t004){#pone.0227890.t004g}

  Knowledge category            Statement (correct answer)                                                                                            Specialty   Provider response (%)        
  ----------------------------- --------------------------------------------------------------------------------------------------------------------- ----------- ----------------------- ---- ----
  Treatment                     Other than supportive care, there are no specific drugs for the treatment of norovirus (TRUE)                         Peds        **96**                  1    4
  GIM                           **90**                                                                                                                0           10                           
  FP                            **92**                                                                                                                0           8                            
  Immunity                      An individual can have repeated norovirus infections (TRUE)                                                           Peds        **92**                  1    7
  GIM                           **87**                                                                                                                1           12                           
  FP                            **87**                                                                                                                0           13                           
  Transmission                  Norovirus is typically spread person-to-person through fecal-oral transmission (TRUE)                                 Peds        **92**                  5    3
  GIM                           **85**                                                                                                                8           8                            
  FP                            **85**                                                                                                                8           7                            
  Environmental persistence     Norovirus can persist on surfaces for days and requires thorough cleaning and disinfection (TRUE)                     Peds        **83**                  6    11
  GIM                           **83**                                                                                                                3           14                           
  FP                            **76**                                                                                                                6           18                           
  Shedding and infectiousness   After the diarrhea and vomiting from norovirus infection resolve, patients are no longer contagious (FALSE)           Peds        **70**                  15   14
  GIM                           **66**                                                                                                                13          21                           
  FP                            **62**                                                                                                                11          26                           
  Burden                        Norovirus is the second most common cause of AGE across all age groups in the United States after rotavirus (FALSE)   Peds        **20**                  61   19
  GIM                           **11**                                                                                                                59          30                           
  FP                            **14**                                                                                                                59          27                           
  Prevention                    Alcohol-based hand sanitizer is an effective method for removing norovirus from hands (FALSE)                         Peds        **49**                  32   18
  GIM                           **38**                                                                                                                40          22                           
  FP                            **34**                                                                                                                45          20                           

GIM = General Internal Medicine

FP = Family Practice

Peds = Pediatricians

Potential barriers to future norovirus vaccines {#sec016}
-----------------------------------------------

Concerns cited as major barriers to implementing a future norovirus vaccine included if the vaccine is not covered by insurance (64--74%) and lack of adequate reimbursement for vaccination (43--50%). Factors that providers believed were 'not at all a barrier' or 'minor barrier' to new vaccine introduction included belief that "my patients won't need this vaccine" (78--90%) and "my patients already get too many vaccines" (89--95%).

Discussion {#sec017}
==========

Our national survey of primary care Peds, FP, and GIM physicians found that only 15% of outpatients with AGE have stool tests ordered during peak AGE season, and diagnostic practices are largely focused on testing for bacteria and parasites and among high-risk patients. Viral pathogens, including norovirus, are much less likely to be identified with current diagnostic testing practices, so traditional surveillance methods that rely on clinician-ordered diagnostic testing will largely underestimate the burden of disease. Additionally, our survey found that most physicians were unaware that norovirus is a leading cause of AGE across all age groups, and that hand sanitizers are ineffective as a prevention tool for norovirus. Closing these knowledge gaps could help support norovirus prevention efforts, including potential introduction of norovirus vaccines.

Our finding that few patients with AGE have stool diagnostic testing aligns with a previous study\[[@pone.0227890.ref015]\], and has important implications for understanding clinician testing practices. FoodNet population-based telephone surveys from 2000--2007 found that only 15% of patients with AGE in the community seek medical attention, and of those, diagnostic testing is requested for only 13% \[[@pone.0227890.ref015]\]. This low stool specimen testing rate reflects clinical decision making in the face of variable patient presentations. In our survey, physicians were more likely to order testing when the patient had a higher risk presentation (e.g., travel history, blood in stool, immunocompromised). Physician specialty was also an important factor; compared with Peds, FP and GIM were more likely to test patients with fever, patients who were sick enough to consider inpatient admission or had a recent hospitalization, and those with history of recent antibiotic use. These factors can be associated with sicker patients, including those with *C*. *difficile* infections\[[@pone.0227890.ref016]\], bringing *C*. *difficile* to the forefront of a differential diagnosis in an adult patient with AGE with relevant symptoms and risk factors. Peds may be less likely to include bacterial pathogens high on the differential for outpatients as viruses cause most AGE and outpatient AGE visits in children \[[@pone.0227890.ref003]\].

These differences in clinical diagnostic testing decisions by patient and specialty are intricately tied to treatment decisions, as the severity of illness as well as the ability to treat illness may lead physicians to order tests. Indeed, all three specialties were more likely to order stool diagnostic testing if they suspected a pathogen that can be treated with antibiotics or anti-parasitics; *C*. *difficile* tests, O&P, and bacterial culture were reported as widely available. On the other hand, suspected viral or non-infectious etiology, such as patients with vomiting without diarrhea, or vomiting and diarrhea together, greatly decreased the likelihood of physician ordered stool diagnostic testing, and tests for viral pathogens were reported as less available and less likely to be ordered.

The stool diagnostic testing practices for patients with AGE identified herein have ramifications for interpreting public health surveillance of AGE pathogens and in pathogen-specific burden of disease estimates, including norovirus. If only a fraction of patients with AGE have stool specimens submitted for testing, and the tests available and ordered by clinicians are heavily weighted towards bacterial and parasitic pathogens, viral pathogens are likely to be underestimated. Additionally, the majority of providers surveyed believe norovirus testing won't change management or is not indicated due to its self-limited nature, and did not know how norovirus testing would be helpful. From a clinical perspective, these beliefs and testing practices reflect a logical and efficient testing algorithm that minimizes the burden on the patient and the healthcare system. In mild to moderate cases of AGE, particularly in the outpatient setting where rapid point of care testing for viral pathogens is not available, testing may not be necessary or helpful for the clinician and patient management. However, from a public health surveillance standpoint, it is clear that current stool diagnostic testing practices in the outpatient setting will underestimate the burden of norovirus disease. While multi-pathogen diagnostic panels are increasingly used in inpatient and research settings \[[@pone.0227890.ref017], [@pone.0227890.ref018]\], the incidence of norovirus in the outpatient setting is approximately one order of magnitude higher than for inpatients\[[@pone.0227890.ref001]\], underscoring the importance of obtaining accurate estimates of norovirus disease in this patient population. Therefore, although our results do not indicate a need for changes in current physician practices, they support using robust surveillance methods to estimate norovirus burden, including prospective, population-based surveillance of laboratory-confirmed disease, as have been employed in outpatient, emergency department, and inpatient settings \[[@pone.0227890.ref003], [@pone.0227890.ref019], [@pone.0227890.ref020]\], to fully appreciate the disease burden of norovirus gastroenteritis. When active prospective evaluations are not possible, AGE burden studies utilizing only International Classification of Disease (ICD)-codes or passive surveillance methods may consider using this survey's findings to weight estimates and place findings into context.

Lack of testing for all possible etiologic pathogens in all patients who present with AGE may also contribute to the physician knowledge gaps about norovirus identified herein. Interestingly, all physician specialties in this survey had knowledge gaps on norovirus burden. The high percentage of providers unaware of the large burden of norovirus disease in the United States could be due in part to the length of time most survey participants have been in practice, as compared to the relatively recent introduction of the rotavirus vaccine in 2006, resulting in norovirus surpassing rotavirus as the leading cause of medically-attended AGE in young children\[[@pone.0227890.ref003]\]. Furthermore, the role of norovirus among cases of AGE has been recognized relatively recently, with the advent and use in research of sensitive and specific RT-PCR assays \[[@pone.0227890.ref001]\]. The shift in pathogen frequencies, together with the lack of widely available diagnostic testing for norovirus as well as vaccine candidates still several years away from implementation, are all likely contributors to this knowledge gap on norovirus burden. Even among physicians for whom norovirus diagnostic tests are available, few reported ordering these tests for outpatients with AGE, further reducing opportunities to recognize norovirus disease burden.

Similarly, the fact that most providers in all specialties did not know that alcohol-based hand sanitizers (ABHS) alone are ineffective for norovirus prevention was striking. This knowledge gap could be due to several factors including variation in hand-hygiene practices among healthcare workers\[[@pone.0227890.ref021]\], clinical guidelines for handwashing outside of those specific for norovirus, and debates in the literature on this topic. The current CDC recommendation for norovirus prevention is to wash hands with soap and water thoroughly, with or without the use of ABHS as an adjunct in between proper handwashings \[[@pone.0227890.ref022]\]. This recommendation is based on the small infectious dose of virus that causes disease\[[@pone.0227890.ref023], [@pone.0227890.ref024]\], incomplete inactivation or reduction in norovirus titers or surrogates following the use of ABHS\[[@pone.0227890.ref025]--[@pone.0227890.ref028]\], and greater effectiveness of handwashing as compared with use of ABHS\[[@pone.0227890.ref029]--[@pone.0227890.ref032]\]. However, there may still be a role for ABHS in norovirus prevention and control; a randomized controlled trial in an elementary school evaluating ABHS together with surface disinfection compared to usual hand-washing and cleaning practices found a reduction in absenteeism due to gastrointestinal illness and surface detection of norovirus in the intervention arm following implementation\[[@pone.0227890.ref033]\]. Additionally, although CDC guidelines recommend handwashing during norovirus outbreaks, they state a preference for ABHS during routine practice if the health care worker's hands are free of any visible soil\[[@pone.0227890.ref021]\]. These nuanced recommendations, together with the ubiquitous presence of ABHS in clinical practice settings in the United States\[[@pone.0227890.ref034]\], may partly explain the knowledge gaps identified in this survey and underscore the need for additional physician education on hand hygiene recommendations.

Our study is also notable for the lack of barriers identified by all physician groups for future norovirus vaccine introduction. Those potential barriers that were identified, including lack of reimbursement or insurance coverage, were no different from a previous study examining adult provider perceptions of barriers to vaccines\[[@pone.0227890.ref035]\]. With the increasing complexity and number of vaccines in both child and adult routine immunization schedules, concerns have been raised that patients may be overwhelmed by the number of shots for themselves and their children. Our survey results indicate that providers support vaccine introduction and do not believe their patients receive too many vaccines. With norovirus vaccine candidates currently in phase I and II clinical trials\[[@pone.0227890.ref005]\], this support will facilitate new vaccine introduction in future years.

This study has limitations. First, the response rate was lower for GIM and FP than for Peds, and some questions on testing and disease burden had high rates of missing for GIM, which limits the generalizability of our data for adult providers. With this exception, this was a nationally representative survey with membership from three major physician organizations, so responses would be expected to generally reflect perceptions of the members within each organization. Second, responses may be subject to recall bias and reflect reported practice; actual practice was not observed. Nonetheless, the responses are in line with studies utilizing other sources and methods. Finally, we did not survey patients or parents regarding future norovirus vaccine introduction; their perception of an additional vaccine may differ from that among providers. Conducting this type of survey among both physicians and patients immediately prior to or after the addition of a norovirus vaccine to routine immunization schedules would provide additional information that will help with successful implementation of a new vaccine.

In conclusion, this nationally representative survey of primary care pediatricians, family medicine and general internal medicine physicians provides new insights on several fronts for norovirus. First, the knowledge gaps on norovirus burden and prevention might be addressed through partnerships with major physician organizations to improve education for both trainees and physicians in practice. Second, the diagnostic practices for patients with AGE should continue to be monitored in light of the increasing availability of multi-pathogen diagnostic panels, and can inform ongoing surveillance to more accurately measure burden of disease. Finally, as norovirus vaccines continue to move through clinical trials, continued implementation of robust active, prospective population-based surveillance will set the stage for successful future introduction of norovirus vaccines.
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###### Additional factors associated with likelihood of stool diagnostic testing for acute gastroenteritis, by specialty.

Peds = Pediatricians; FP = Family Practice; GIM = General Internal Medicine. \*p\<0.01 for differences between specialties.

(PDF)
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